This article explores how digital maturity in process design and parameter management can drive significant time and cost ...

When Genentech licensed experimental drug ... large-scale experiments and we use these experiments in order to understand the biology.'" Executives and industry experts caution that AI adoption ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger ...

Article on tech giants' FY25 capex projections and AI data center advances. Nvidia Corporation stock analysis included. Click ...

An area that offers hope to accelerate an understanding of cancer and speed up drug development ... use of low-cost AI tools on digital pathology slides, rather than large-scale genomic sequencing ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

At this time, I would like to welcome everyone to the SelectQuote's fiscal second quarter 2025 earnings call. All lines have ...

Quantum computing matures but relies on academia and government. Industry competition grows, AI diverts focus, market projected to surpass $10B by 2045.